Nature Medicine Publishes Interim Results From Gritstone Bio's Phase 1/2 Study of "Off-the-Shelf" Neoantigen Vaccine Platform (SLATE)

PDF Version -- Paper details vaccine design optimization process of Gritstone's "off-the-shelf" or shared neoantigen vaccine platform, SLATE ---- Discovery of a novel immunodominance hierarchy of

Gritstone BioApr 15 12:00

Gritstone Bio, Inc. (GRTS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors...

Stockhouse Apr 8 23:00

Gritstone Bio Presented An Update On Its T Cell Epitope Discovery Platform, EDGE, At AACR 2024, Highlighting Improvements In Prediction Of Peptide Presentation By HLA Class I, Associated With CD8+ T Cells, Since Initial Results In 2018

Gritstone Bio Presented An Update On Its T Cell Epitope Discovery Platform, EDGE, At AACR 2024, Highlighting Improvements In Prediction Of Peptide Presentation By HLA Class I, Associated With CD8+ T C

BenzingaApr 8 19:26

Gritstone Bio to Participate in Upcoming Investor and Scientific Conferences

PDF Version EMERYVILLE, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world's most potent vaccines

Gritstone BioApr 8 12:00

Gritstone Bio Presents Improvements to EDGE Platform at AACR 2024

PDF Version -- State-of-the-art neoantigen prediction platform (EDGE) now predicts HLA Class I presentation of epitopes with >80% accuracy ---- Newly developed EDGE-II model achieves superior pre

Gritstone BioApr 8 12:00

JMP Securities Maintains Market Outperform on Gritstone Bio, Raises Price Target to $5

JMP Securities analyst Roy Buchanan maintains Gritstone Bio (NASDAQ:GRTS) with a Market Outperform and raises the price target from $4 to $5.

BenzingaApr 3 02:09